Brazil's National Health Surveillance Agency (Anvisa) has officially approved a new version of the diabetes medication Mounjaro, specifically designed for type 2 diabetes treatment. The approval was published in the Official Gazette of the Union on Wednesday, confirming that the new formulation, known as Mounjaro Multidose, enables patients to administer multiple doses via a single applicator pen, as opposed to the previous single-use model. This new development aims to improve the convenience and ease of medication administration for patients.

The approval comes under Resolution-RE No. 1,041 from Anvisa's General Management of Medications, granting registration to Eli Lilly do Brasil for a drug based on tirzepatide. The approved version features six different concentrations available in a subcutaneous injection format, including 4.17 mg/mL, 8.33 mg/mL, 12.5 mg/mL, 16.7 mg/mL, 20.8 mg/mL, and 25 mg/mL. This new multidose option is expected to simplify the treatment process for those managing diabetes, as it allows for easier dosing without the need for multiple pens.

With the registration valid for 24 months, this step represents a significant advancement in diabetes care in Brazil. Patients and healthcare providers may find that the multidose feature enhances adherence to treatment regimens, thus potentially improving health outcomes for those living with type 2 diabetes. Ultimately, this approval underscores the ongoing efforts to innovate in the field of diabetes management and medications.